



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

**PEER-REVIEW REPORT**

**Name of journal:** World Journal of Nephrology

**Manuscript NO:** 38781

**Title:** Novel PDGFR and VEGFR dual kinase inhibitor for fibropolycystic hepato-renal disease

**Reviewer's code:** 02741591

**Reviewer's country:** Egypt

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-25

**Date reviewed:** 2018-03-25

**Review time:** 1 Hour

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                                  |
|---|---|--|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing                 | <input type="checkbox"/> Accept                    | Peer-Review:  |
| <input type="checkbox"/> Grade B: Very good       | <input checked="" type="checkbox"/> Grade B: Minor language polishing | (High priority)                                    | <input checked="" type="checkbox"/> Anonymous             |
| <input checked="" type="checkbox"/> Grade C: Good |   | <input type="checkbox"/> Accept                    | <input type="checkbox"/> Onymous                          |
| <input type="checkbox"/> Grade D: Fair            | <input type="checkbox"/> Grade C: A great deal of language polishing  | (General priority)                                 | Peer-reviewer's expertise on the topic of the manuscript: |
| <input type="checkbox"/> Grade E: Do not publish  | <input type="checkbox"/> Grade D: Rejection                           | <input checked="" type="checkbox"/> Minor revision | <input type="checkbox"/> Advanced                         |
|   |   | <input type="checkbox"/> Major revision            | <input type="checkbox"/> General                          |
|   |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> No expertise                     |
|   |   |  | Conflicts-of-Interest:                                    |
|   |   |  | <input type="checkbox"/> Yes                              |
|   |   |  | <input type="checkbox"/> No                               |

**SPECIFIC COMMENTS TO AUTHORS**

The idea of the study is interesting and may serve as an interesting bridge toward hepato-renal transplantation in patients with fibropolycystic disease. The title should be refined to best reflect the content of the study inhibiting the PDGFR and

VEGFR/KDR. The abstract is truncated (178 words). It could be expanded and structured to be able to stand alone regardless the article. The methods and results could be better wrapped up. The number of figures is too much (n=11) for an original article. They could better be merged. Constructing a table would be useful to present the results presented in text format. . The discussion is lengthy. It should be more focused and shortened. The resolution of figures 1, 2, 5, 8, 9 and 10 could be improved. The references could be slightly reduced in number to fit for an original article.

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

### PEER-REVIEW REPORT

**Name of journal:** World Journal of Nephrology

**Manuscript NO:** 38781

**Title:** Novel PDGFR and VEGFR dual kinase inhibitor for fibropolycystic hepato-renal disease

**Reviewer's code:** 01805500

**Reviewer's country:** Italy

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-25

**Date reviewed:** 2018-03-26

**Review time:** 20 Hours

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                      |
|---|---|--|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing       | <input type="checkbox"/> Accept                    | Peer-Review:                                  |
| <input type="checkbox"/> Grade B: Very good       | <input checked="" type="checkbox"/> Grade B: Minor language | (High priority)                                    | <input checked="" type="checkbox"/> Anonymous |
| <input checked="" type="checkbox"/> Grade C: Good | polishing   | <input type="checkbox"/> Accept                    | <input type="checkbox"/> Onymous              |
| <input type="checkbox"/> Grade D: Fair            | <input type="checkbox"/> Grade C: A great deal of           | (General priority)                                 | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not          | language polishing  | <input checked="" type="checkbox"/> Minor revision | topic of the manuscript:                      |
| publish   | <input type="checkbox"/> Grade D: Rejection                 | <input type="checkbox"/> Major revision            | <input type="checkbox"/> Advanced             |
|   |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> General              |
|   |   |  | <input type="checkbox"/> No expertise         |
|   |   |  | Conflicts-of-Interest:                        |
|   |   |  | <input type="checkbox"/> Yes                  |
|   |   |  | <input type="checkbox"/> No                   |

#### SPECIFIC COMMENTS TO AUTHORS

Authors are kindly requested to present their data as means plus/minus SD but not SEM, because readers are interested in knowing the dispersion of values and not the precision of the mean, due to the paucity of observations. I haven't read any word about the side

effects in this model of the studied molecule. Was the possible toxicity evaluated and at what organ-level?

#### INITIAL REVIEW OF THE MANUSCRIPT

*Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

*BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

### PEER-REVIEW REPORT

**Name of journal:** World Journal of Nephrology

**Manuscript NO:** 38781

**Title:** Novel PDGFR and VEGFR dual kinase inhibitor for fibropolycystic hepato-renal disease

**Reviewer's code:** 02438768

**Reviewer's country:** China

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-25

**Date reviewed:** 2018-03-29

**Review time:** 3 Days

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                      |
|---|---|--|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing       | <input type="checkbox"/> Accept                    | Peer-Review:                                  |
| <input type="checkbox"/> Grade B: Very good       | <input checked="" type="checkbox"/> Grade B: Minor language | (High priority)                                    | <input checked="" type="checkbox"/> Anonymous |
| <input checked="" type="checkbox"/> Grade C: Good | polishing   | <input type="checkbox"/> Accept                    | <input type="checkbox"/> Onymous              |
| <input type="checkbox"/> Grade D: Fair            | <input type="checkbox"/> Grade C: A great deal of           | (General priority)                                 | Peer-reviewer's expertise on the              |
| <input type="checkbox"/> Grade E: Do not          | language polishing  | <input checked="" type="checkbox"/> Minor revision | topic of the manuscript:                      |
| publish   | <input type="checkbox"/> Grade D: Rejection                 | <input type="checkbox"/> Major revision            | <input type="checkbox"/> Advanced             |
|   |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> General              |
|   |   |  | <input type="checkbox"/> No expertise         |
|   |   |  | Conflicts-of-Interest:                        |
|   |   |  | <input type="checkbox"/> Yes                  |
|   |   |  | <input type="checkbox"/> No                   |

#### SPECIFIC COMMENTS TO AUTHORS

Comments for ESPS Manuscript NO 38781 This is an interesting topic. The followings are my several major and minor concerns. Major concerns: 1. Too many figures used in this article should be merged. 2. The authors only emphasized the possible effects of this



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

inhibitor (ANG3070) in the PCK rat model of ARPKD-CHF, but they should also state its potential toxic effects. Minor concerns: 1. The format of this manuscript should be revised according to WJN's requirement. 2. The "Core tip" should be added in the text.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Nephrology

**Manuscript NO:** 38781

**Title:** Novel PDGFR and VEGFR dual kinase inhibitor for fibropolycystic hepato-renal disease

**Reviewer's code:** 02441021

**Reviewer's country:** Egypt

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-25

**Date reviewed:** 2018-04-03

**Review time:** 8 Days

| SCIENTIFIC QUALITY                                | LANGUAGE QUALITY  | CONCLUSION   | PEER-REVIEWER STATEMENTS                                  |
|---|---|--|---|
| <input type="checkbox"/> Grade A: Excellent       | <input type="checkbox"/> Grade A: Priority publishing                 | <input type="checkbox"/> Accept                    | Peer-Review:  |
| <input type="checkbox"/> Grade B: Very good       | <input checked="" type="checkbox"/> Grade B: Minor language polishing | (High priority)                                    | <input type="checkbox"/> Anonymous                        |
| <input type="checkbox"/> Grade C: Good            |   | <input type="checkbox"/> Accept                    | <input checked="" type="checkbox"/> Onymous               |
| <input checked="" type="checkbox"/> Grade D: Fair | <input type="checkbox"/> Grade C: A great deal of language polishing  | (General priority)                                 | Peer-reviewer's expertise on the topic of the manuscript: |
| <input type="checkbox"/> Grade E: Do not publish  | <input type="checkbox"/> Grade D: Rejection                           | <input type="checkbox"/> Minor revision            | <input type="checkbox"/> Advanced                         |
|   |   | <input checked="" type="checkbox"/> Major revision | <input type="checkbox"/> General                          |
|   |   | <input type="checkbox"/> Rejection                 | <input type="checkbox"/> No expertise                     |
|   |   |  | Conflicts-of-Interest:                                    |
|   |   |  | <input type="checkbox"/> Yes                              |
|   |   |  | <input type="checkbox"/> No                               |

### SPECIFIC COMMENTS TO AUTHORS

Several language and spelling mistakes • Abstract -Very defective, did not include the work résumé. • Animal Model = Angion Biomedica animal use and care committee.....Elaborate • Discussion Lengthy and unfocussed



7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

##### *BPG Search:*

- The same title
- Duplicate publication
- Plagiarism
- No

## Answers to Peer Review Comments

**At first the authors are thankful and greatly appreciate for reviewing the manuscript and raising some comments.** Peer-Review considered that the idea of the study is interesting and the authors aimed to determine a novel small molecule PDGFR+ VEGFR (KDR) dual kinase inhibitor, ANG3070 may have therapeutic benefit and reduce the number of hepato-renal transplants in patients with fibropolycystic kidney disease, ARPKD-CHF. The following changes have been made according to the reviewer's comments.

- Title of manuscript is changed to  
A novel PDGFR and VEGFR dual kinase inhibitor for fibropolycystic hepato-renal disease.
- ARRIVE Guidelines Checklist - page numbers - pdf file attached.
- Abstract is revised describing AIM, METHODS, RESULTS and CONCLUSION without exceeding the word count limits for publication.
- Potential toxic effects of ANG3070 compound is addressed
- Decreased the discussion part with slight modification and adjusted references.
- The number of figures decreased by merging and removing one figure.
- All the data is presented as Means  $\pm$  SD
- References formatted and added PubMed ID and/or DOI numbers if available.
- A new conflict of interest statement attached.
- A new audio-clip attached in MP3 format.
- Now, the authors have revised the manuscript to address all the peer-review comments for publication in the *WJN*.